Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
about
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.Challenges faced when identifying patients for combination immunotherapy.Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.Trial watch: Immune checkpoint blockers for cancer therapy.Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.Financial toxicity and implications for cancer care in the era of molecular and immune therapies.
P2860
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@ast
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@en
type
label
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@ast
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@en
prefLabel
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@ast
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@en
P2093
P2860
P356
P1476
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
@en
P2093
Alberto J Montero
Christine G Kohn
Christopher R Flowers
Daniel A Goldstein
Qiushi Chen
Simon B Zeichner
P2860
P304
P356
10.1200/JCO.2016.69.6336
P407
P577
2017-02-21T00:00:00Z